FindTrial
Sign In

Randomized, placebo-controlled, blindtrial to evaluate tolerability and impact on skin hydration, skin density, skin roughness and skin elasticity of ELASTEN®, a dietary supplement containing special collagen peptides, compared to placebo (without nutritive substances), including 72 female volunteers with healthy skin aged 35 years or older

Randomized, placebo-controlled, blindtrial to evaluate tolerability and impact on skin hydration, skin density, skin roughness and skin elasticity of ELASTEN®, a dietary supplement containing special collagen peptides, compared to placebo (without nutritive substances), including 72 female volunteers with healthy skin aged 35 years or older

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00015664
Enrollment
72
Registered
2018-10-04
Start date
2017-10-16
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers

Interventions

Group 1: ELASTEN® (drinking ampules, ingredients: collagen peptides, acerola fruit extract, vitamin C, zinc, vitamin E, Biotin), dosage: one drinking ampule once a day for 12 weeks Group 2: Placebo (d

Sponsors

QUIRIS Healthcare GmbH & Co. KG
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) skin type: any, (2) Written informed consent of volunteers or legal guardian available, (3) Volunteers must be able to communicate with the investigator and to understand and follow requirement of the clinical trial

Exclusion criteria

Exclusion criteria: (1) Severe or chronic skin inflammation, (2) Severe internal or chronic diseases, (3) Intake of drugs which can impair the skin reaction (e.g. glucocorticoids, antiallergics, immunomodulators), (4) Application of preparations or care products containing an active substance 7-10 days before study onset, (5) Severe allergies or ever occured serious adverse effects by cosmetic preparations, (6) Sunbathing or solarium visits during the study, (7) Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
Evaluation of tolerability: Assessment of skin reactions and possible other adverse effects in the questionnaire, from study onset up to 30 days after study end—

Secondary

MeasureTime frame
Evaluation of efficacy (at T0, T12 and T16): - Skin hydration (corneometry, forearm) - Skin elasticity (Cutometer, forearm) - Skin roughness (PRIMOS replicas, face) - Skin density (sonographic measurements, thigh)—

Countries

Germany

Contacts

Public ContactJan-Christoph Kattenstroth

QUIRIS Healthcare GmbH & Co. KG

info@quiris.de05241 403 430

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026